EYEPOINT PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.75 USD | +3.65% |
|
-5.10% | -27.52% |
| Apr. 02 | EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board | CI |
| Mar. 18 | EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 167.6 | 99.56 | 414.9 | 119.3 | 1,088 | 834.7 | - | - |
| Enterprise Value (EV) 1 | 167.6 | 99.56 | 414.9 | 119.3 | 806.6 | 619.9 | 486.4 | 343.5 |
| P/E ratio | -2.87 x | -1.86 x | -6.03 x | -1.28 x | -12.7 x | -10.9 x | -6.42 x | -6.11 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 8.23 x | 2.89 x | 11.2 x | 2.88 x | 23.6 x | 17.7 x | 48.1 x | 62.3 x |
| EV / Revenue | 8.23 x | 2.89 x | 11.2 x | 2.88 x | 17.5 x | 13.2 x | 28 x | 25.6 x |
| EV / EBITDA | -4.12 x | -2.87 x | - | - | - | 3.88 x | 2.6 x | 1.46 x |
| EV / FCF | -2.94 x | -6.73 x | -8.26 x | -1.78 x | -502 x | -38 x | -4.09 x | -2.4 x |
| FCF Yield | -34% | -14.9% | -12.1% | -56.3% | -0.2% | -2.63% | -24.4% | -41.7% |
| Price to Book | - | - | - | - | 4.26 x | 4.77 x | 3.06 x | 2.51 x |
| Nbr of stocks (in thousands) | 10,812 | 15,130 | 33,894 | 34,083 | 47,074 | 49,831 | - | - |
| Reference price 2 | 15.50 | 6.580 | 12.24 | 3.500 | 23.11 | 16.75 | 16.75 | 16.75 |
| Announcement Date | 3/5/20 | 3/4/21 | 3/3/22 | 3/2/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 20.36 | 34.44 | 36.94 | 41.4 | 46.02 | 47.06 | 17.36 | 13.39 |
| EBITDA 1 | -40.69 | -34.64 | - | - | - | 159.9 | 186.9 | 235.3 |
| EBIT 1 | -47.86 | -37.29 | -55.28 | -78.94 | -75.07 | -89.58 | -147 | -163.4 |
| Operating Margin | -235.02% | -108.28% | -149.64% | -190.65% | -163.13% | -190.34% | -846.84% | -1,219.81% |
| Earnings before Tax (EBT) 1 | -56.79 | -45.39 | -58.42 | -102.3 | -70.71 | -75.97 | -137.7 | -164.3 |
| Net income 1 | -56.79 | -45.39 | -58.42 | -102.3 | -70.8 | -78.98 | -143.6 | -164.4 |
| Net margin | -278.88% | -131.82% | -158.14% | -246.97% | -153.84% | -167.82% | -826.93% | -1,227.39% |
| EPS 2 | -5.400 | -3.540 | -2.030 | -2.740 | -1.820 | -1.533 | -2.609 | -2.739 |
| Free Cash Flow 1 | -56.91 | -14.8 | -50.25 | -67.16 | -1.608 | -16.3 | -118.8 | -143.2 |
| FCF margin | -279.46% | -42.97% | -136.04% | -162.19% | -3.49% | -34.63% | -684.39% | -1,069.39% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 3/4/21 | 3/3/22 | 3/2/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9.059 | 11.54 | 9.294 | 11.56 | 10.01 | 10.53 | 7.683 | 9.105 | 15.2 | 14.03 | 8.926 | 8.791 | 9.315 | 8.228 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | 42 | - |
| EBIT 1 | -15.31 | -18.05 | -18.28 | -19.22 | -18.4 | -23.04 | -21.55 | -22.76 | -14.4 | -16.35 | -21.47 | -23.24 | -25.98 | -29.42 |
| Operating Margin | -169.04% | -156.36% | -196.73% | -166.16% | -183.76% | -218.7% | -280.54% | -249.98% | -94.71% | -116.58% | -240.57% | -264.32% | -278.87% | -357.59% |
| Earnings before Tax (EBT) 1 | -16.7 | -19.43 | -20.98 | -19.41 | -18.42 | -43.45 | -21.16 | -22.92 | -12.61 | -14.02 | -18.4 | -20.18 | -23.03 | -26.22 |
| Net income 1 | -16.7 | -19.43 | -20.98 | -19.41 | -18.42 | -43.45 | -21.16 | -22.92 | -12.61 | -14.1 | -18.4 | -20.18 | -23.03 | -26.22 |
| Net margin | -184.29% | -168.33% | -225.69% | -167.8% | -183.98% | -412.53% | -275.47% | -251.73% | -82.96% | -100.51% | -206.1% | -229.6% | -247.26% | -318.62% |
| EPS 2 | -0.5800 | -0.5900 | -0.5600 | -0.5200 | -0.4900 | -1.160 | -0.5600 | -0.6100 | -0.3300 | -0.3300 | -0.3589 | -0.4029 | -0.4524 | -0.5490 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 3/3/22 | 5/4/22 | 8/3/22 | 11/2/22 | 3/2/23 | 5/3/23 | 8/2/23 | 11/1/23 | 3/7/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | - | 281 | 215 | 348 | 491 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -56.9 | -14.8 | -50.3 | -67.2 | -1.61 | -16.3 | -119 | -143 |
| ROE (net income / shareholders' equity) | - | - | - | - | -39% | -44.4% | -71.9% | -59.7% |
| ROA (Net income/ Total Assets) | - | - | - | - | -26.4% | -33.9% | -59.4% | -51.7% |
| Assets 1 | - | - | - | - | 267.8 | 232.8 | 241.7 | 317.9 |
| Book Value Per Share 2 | - | - | - | - | 5.430 | 3.510 | 5.470 | 6.670 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.21 | 0.36 | 0.16 | 2.15 | 3.48 | 2.3 | 2.33 | 2.73 |
| Capex / Sales | 1.05% | 1.05% | 0.42% | 5.19% | 7.57% | 4.89% | 13.44% | 20.41% |
| Announcement Date | 3/5/20 | 3/4/21 | 3/3/22 | 3/2/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
16.75
USD
Average target price
43.89
USD
Spread / Average Target
+162.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.52% | 835M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- EYPT Stock
- Financials EyePoint Pharmaceuticals, Inc.
